Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

NCT07535489 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderately to Severely Active Ulcerative Colitis (UC)

Interventions

DRUG: IPG11406
DRUG: Placebo

Sponsor

Nanjing Immunophage Biotech Co., Ltd

Collaborators

[object Object]